Journal: Nature Communications

Article Title: Rosiglitazone and trametinib exhibit potent anti-tumor activity in a mouse model of muscle invasive bladder cancer

doi: 10.1038/s41467-024-50678-2

Figure Lengend Snippet: A , B Expression of activated Caspase-3 in tumors of mice exposed to BBN for 5 months then treated with vehicle for 7 days, image shown with A and without B Ecad. C , D Expression of activated Caspase-3 in 5 M BBN tumors treated with Rosi+Tram for 7 days, image shown with C and without D Ecad. E Bar graph showing the percentage of cells expressing activated caspase-3 in BBN-induced tumors treated for 7 days with vehicle ( n = 3) or Rosi+Tram ( n = 3). Data given as means ± SD, significance calculated using two-tailed Mann-Whitney test, ***p = 0.0001. F Bar graph showing the percentage of cells expressing Ki67 in BBN-treated mice after vehicle ( n = 3) or Rosi+Tram ( n = 3) for 7 days. Data given as means ± SD, significance calculated using two-tailed Mann-Whitney test, ****p < 0.0001. G Apoptosis assayed by AnnexinV-eFluor450/7-AAD double staining in BBN963 cells treated with DMSO, Rosi, Tram, or combined Rosi+Tram for 72 h. Cells undergoing early apoptosis were AnnexinV+/7-AAD: late apoptosis: AnnexinV+/7-AAD+. H Heatmap showing normalized expression of proapoptotic genes, caspases, and pro-survival genes in Rosi+Tram treated BBN963 cells compared to controls based on RNAseq analysis. I – L Decreased proliferation determined by Ki67 staining in BBN963 cells after Rosi ( n = 4) J , Tram ( n = 4) K , or combined Rosi+Tram ( n = 4) L compared to controls ( n = 4) I . M – P Down-regulation of Ccnd1 in BBN963 cells after treatment with Rosi N , Tram O , or Rosi+Tram P compared to controls M . Scale bars: 50 µm. Q Heatmap of normalized gene expression showing down-regulation of Ccnd1 and genes that positively regulate cell cycle progression and up-regulation of genes that inhibit progression in BBN963 cells treated with Rosi+Tram for 72 h compared to DMSO treated controls. R Bar graph showing number of Ccnd1-positive BBN963 cells after 72-h treatment with DMSO ( n = 4), Rosi ( n = 4), Tram ( n = 4), and combined Rosi+Tram ( n = 4). Data given as means ± SD, significance calculated using two-tailed unpaired Welch’s t-test, *** p = 0.0006, ****p < 0.0001. Source data are provided as a Source Data file. Cartoons in Fig. 3 created with BioRender.com released under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International license ( https://creativecommons.org/licenses/by-nc-nd/4.0/deed.en ).

Article Snippet: Rabbit Monoclonal Anti- Cyclin D1 , Abcam , Cat#ab16663 , SP4 , 1:200.

Techniques: Expressing, Two Tailed Test, MANN-WHITNEY, Double Staining, Staining

Journal: Nature Communications

Article Title: Rosiglitazone and trametinib exhibit potent anti-tumor activity in a mouse model of muscle invasive bladder cancer

doi: 10.1038/s41467-024-50678-2

Figure Lengend Snippet:

Article Snippet: Rabbit Monoclonal Anti- Cyclin D1 , Abcam , Cat#ab16663 , SP4 , 1:200.

Techniques:

Journal: Oncology Letters

Article Title: Proteomic insights into the regulatory function of ARID1A in colon cancer cells

doi: 10.3892/ol.2024.14525

Figure Lengend Snippet: Involvement of ARID1A and altered proteins in the Wnt signaling pathway. (A) Wnt signaling pathway information generated using Kyoto Encyclopedia of Genes and Genomes (hsa04310). The pathway is illustrated using data from the KEGG database ( https://www.genome.jp/pathway/hsa04310 ) . Red boxes indicate differentially altered proteins. (B) Western blot images for c-Myc, TCF1/TCF7 and cyclin D1, with GAPDH as the loading control. (C) Band intensity of proteins relative to GAPDH. The bar graph represents the mean ± standard deviation (n=3 per group). *P<0.05. ARID1A, AT-rich interacting domain-containing protein 1A; TCF, T cell factor; O/E, overexpression; MW, molecular weight.

Article Snippet: The membrane was incubated with 5% skimmed milk in PBS at 25°C for 1 h. Subsequently, it was incubated with rabbit polyclonal anti-ARID1A (1:1,000; cat. no. HPA005456; Sigma-Aldrich; Merck KGaA), rabbit monoclonal anti-c-Myc (1:1,000; cat. no. 5605; Cell Signaling Technology, Inc.), rabbit monoclonal anti-T cell factor (TCF)1/7 (1:1,000; cat. no. 2203; Cell Signaling Technology, Inc.), rabbit monoclonal anti-cyclin D1 (1:1,000; cat. no. 2978; Cell Signaling Technology, Inc.), rabbit polyclonal anti-zinc and ring finger 3 (ZNRF3; 1:1,000; cat. no. DF14289; Affinity Biosciences), or mouse monoclonal anti-GAPDH (1:5,000; cat. no. ab8245; Abcam) antibodies at 4°C overnight.

Techniques: Generated, Western Blot, Control, Standard Deviation, Over Expression, Molecular Weight

Journal: iScience

Article Title: TERC promotes non-small cell lung cancer progression by facilitating the nuclear localization of TERT

doi: 10.1016/j.isci.2024.109869

Figure Lengend Snippet: Knockdown of TERC inhibits the nuclear functions of TERT (A) Relative telomere repeat number in NSCLC cells. Cellular DNA was extracted from A549, H322, H460, and H1299 cells without (ctrl) or with TERC knockdown (TERC-si1, TERC-si2), or treated with 10 μM BIBR1532, and qPCR was performed for each extract to obtain the relative telomere repeat number as described previously, using 36B4 as the single-copy gene control. (B) Binding of TERT at the indicated genomic regions. ChIP was performed with TERT antibody, or IgG as control, and qPCR was run with primers specific for the tested target regions in A549 cells without or with TERC knockdown, or treated with 10 μM BIBR1532. Reported values correspond to the signal for each site relative to that of the IgG control. (C) Gene expression analysis of pre-tRNA, pre-rRNA, rRNA, as well as c-Myc, cyclin D1, and VEGF mRNA transcripts in A549 cells. RT-qPCR was performed, and U6 served as the control for pre-tRNA, pre-rRNA, and rRNA transcripts, while β-actin served as the control for mRNA transcripts. Data in (A–C) were presented as mean ± SD ( n ≥ 2), and p values between the control and the TERC-si1/2 groups were calculated by Student’s t -test. (D) Gene expression analysis in xenograft tumors from A549 cells without (control) or with TERC stably knocked down (TERC-sh). Data were presented as individual dots and mean ± SD ( n = 4), and p values were determined by Student’s t -test. (E) Protein expression of cyclin D1. Western blotting was used to detect cyclin D1 levels in A549 cells. Histone H3 served as the loading control.

Article Snippet: Rabbit monoclonal (92G2) anti-Cyclin D1 , Cell Signaling Technology , Cat#2978; RRID: AB_2259616.

Techniques: Binding Assay, Expressing, Quantitative RT-PCR, Stable Transfection, Western Blot

Journal: iScience

Article Title: TERC promotes non-small cell lung cancer progression by facilitating the nuclear localization of TERT

doi: 10.1016/j.isci.2024.109869

Figure Lengend Snippet:

Article Snippet: Rabbit monoclonal (92G2) anti-Cyclin D1 , Cell Signaling Technology , Cat#2978; RRID: AB_2259616.

Techniques: Virus, Recombinant, Modification, Immunoprecipitation, Transfection, Membrane, DNA Purification, SYBR Green Assay, Isolation, Staining, Methylation, Software

Journal: Cell Reports Medicine

Article Title: Comprehensive proteogenomic characterization of rare kidney tumors

doi: 10.1016/j.xcrm.2024.101547

Figure Lengend Snippet:

Article Snippet: Rabbit Monoclonal IgG Human Cyclin D1 , Cell Marque , Catalog: 241R-18 RRID: AB_1158233.

Techniques: Software

Journal: Aging (Albany NY)

Article Title: Exploring the anti-atherosclerosis mechanism of ginsenoside Rb1 by integrating network pharmacology and experimental verification

doi: 10.18632/aging.205680

Figure Lengend Snippet: Molecular docking between ginsenoside Rb1 and core targets protein. ( A ) The binding energy of molecular docking. ( B ) CCND1 and ginsenoside Rb1 molecular docking visualization.

Article Snippet: According to the manufacturer’s instructions, prewash beads two times with 1X Modified Coupling Buffer and bind with 5 μg cyclin D1 rabbit mAb (bsm-52046R, dilution ratio 1:200, Bioss, USA) or CDK4 mouse mAb (bsm-52028M, dilution ratio 1:200, Bioss, USA) specific primary antibody for 15 min. Next, wash beads three times with 1X Modified Coupling Buffer and crosslink antibody to beads with DSS for 30 min. Then, wash beads three times with Elution Buffer followed by two washes with IP Lysis/Wash Buffer.

Techniques: Binding Assay

Journal: Aging (Albany NY)

Article Title: Exploring the anti-atherosclerosis mechanism of ginsenoside Rb1 by integrating network pharmacology and experimental verification

doi: 10.18632/aging.205680

Figure Lengend Snippet: Ginsenoside Rb1 inhibited the interaction of CCND1 and CDK4 complex.

Article Snippet: According to the manufacturer’s instructions, prewash beads two times with 1X Modified Coupling Buffer and bind with 5 μg cyclin D1 rabbit mAb (bsm-52046R, dilution ratio 1:200, Bioss, USA) or CDK4 mouse mAb (bsm-52028M, dilution ratio 1:200, Bioss, USA) specific primary antibody for 15 min. Next, wash beads three times with 1X Modified Coupling Buffer and crosslink antibody to beads with DSS for 30 min. Then, wash beads three times with Elution Buffer followed by two washes with IP Lysis/Wash Buffer.

Techniques: